Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GGT1 | P19440 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021095 | 1.00 | CYP1A2 (0.38) | CYP1A2CYP2D6ALDH1A1TP53TSHR | |
| Hydrochloric Acid SCHEMBL28509134 | 0.98 | CYP1A2 (0.36) | CYP1A2CYP2D6ALDH1A1TP53TSHR | |
| SCHEMBL15917740 | 0.82 | CYP1A2 (0.39) | CYP1A2CYP2D6ALDH1A1TP53TSHR | |
| Acetic Acid SCHEMBL9130936 | 0.75 | ALDH1A1 (0.32) | CYP1A2CYP2D6ALDH1A1TP53TSHR | |
| SCHEMBL574756 | 0.74 | — | — | |
| SCHEMBL19862759 | 0.74 | — | — | |
| SCHEMBL594190 | 0.74 | — | — | |
| SCHEMBL21641518 | 0.74 | — | — | |
| SCHEMBL9271747 | 0.74 | — | — | |
| SCHEMBL161194 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286763-A1 | AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7550506-B2 | Amino acid derived prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1781596-B1 | AMINO ACID DERIVED PRODRUGS OF PROPOFOL COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1781596-A1 | AMINO ACID DERIVED PRODRUGS OF PROPOFOL COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060100160-A1 | Amino acid derived prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006017352-A1 | AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100160-A1 | Amino acid derived prodrugs of propofol, compositions and uses thereof | SLC1A1, SLC1A5, SLC1A2 | CYP1A2 169/4885CYP2D6 40/4885ALDH1A1 3969/4885 |
| US-20090286763-A1 | AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF | SLC1A1, SLC1A5, SLC1A2 | CYP1A2 169/4885CYP2D6 40/4885ALDH1A1 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.